GLP-3

GLP-3 (Reta)

What is it? GLP-3 is an investigational peptide that activates three hormone receptors: GLP-1, GIP, and glucagon. It is being studied for its potential effects on weight management and metabolic health. GLP-3 is not approved by Health Canada or the FDA and remains an investigational drug.

Potential Research Benefits

May support significant weight loss in clinical research

May reduce appetite and increase feelings of fullness

May increase energy expenditure through glucagon receptor activity

May improve blood sugar regulation

May support improvements in metabolic health

May help reduce waist circumference and body fat in clinical studies

May improve cardiovascular and metabolic risk markers

Typical Research Cycle

Research Duration: 12–48 weeks in clinical trials

Research protocols typically begin with a low dose followed by gradual dose escalation every 4 weeks to improve tolerability.

The optimal dosing schedule continues to be evaluated in ongoing clinical studies.

Storage

Refrigerate after reconstitution (2–8°C)

Protect from light

Use within approximately 28 days after mixing (following sterile handling practices)